To surprise everyone later, Zhang Heng continued to officially run the project under the name Entecavir. In reality, he had secretly replaced the key component and planned to give everyone a major surprise when the results came out.
He especially wanted to earn Wu Ting's admiration and congratulations.
...
...
「Time slowly passed.」
Several months had passed since Pfizer's new drug entered the market. Many patients had already taken it and seen significant results.
The Hepatic Tumor Surgery department at City First Hospital had also introduced this new drug, and its doctors began to use it in clinical practice.
Wu Ting encountered the drug in his work as well.
Looking at the new drug's information leaflet, Wu Ting couldn't help but feel a sense of admiration.
The last time he had seen Xu Kunlin, the First Scientist of the Jin Pharmaceutical Group's Jin Country Research Center, an entry had dropped from him: Pharmaceutical Insights for Sorafenib (Purple)!
